CoDa Therapeutics Inc.

Industry

  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
  • Biotechnology
    • Large Molecule
    • Antisense, Oligonucleotides
See more in Biomedtracker

Latest on CoDa Therapeutics Inc.

Scrip

Finance Watch: Morphic's 'Smooth' Progress With Oral Integrin Inhibitors Justifies $80m Series B

 
• By Mandy Jackson

Coming from a fairly large firm – Cubist Pharmaceuticals Inc. – before its $8.4bn acquisition by Merck & Co. Inc. in 2014, Morphic Therapeutic Inc. President and CEO Praveen Tipirneni said he ex

Scrip

Russian Sovereign Fund Rusnano Invests $20 Million In CoDa Therapeutics

 
• By Wendy Diller

San Diego, Calif.-based wound healing company CoDa Therapeutics Inc. has become the first Domain Associates LLC portfolio company to benefit from the venture capital firm’s new partnership with

Pink Sheet

Regado Snags $51M From Venture Funding Led By Rusnano

 
• By Lisa LaMotta

Regado Biosciences Inc. has garnered the means to initiate a pricey Phase III trial for its lead drug; opting to seek funds from venture investors rather than pursue any of the partnering options it

Scrip

Domain/Rusnano starts, unmusically, with $40m investment in CoDa

 
• By Pial Ganguli

As part of their strategic investment partnership, Domain Associates and RusnanoMedInvest (a subsidiary of Rusnano) have made their first joint investment of nearly $40 million into San Diego, Califor